Daily treatment with ATH-1105 10 mg/kg or 20 mg/kg for 2 months elicited a significant and dose-dependent decrease in the concentrations of both TNF-α (1.45 ± 0.07-fold change from WT for 20 mg/kg) and IL-6 (1.52 ± 0.13-fold change from WT for 20 mg/kg) in plasma (Figures 5K,L), suggesting reduced inflammation related to ALS-like pathology. Here, IL6 is linked to amyotrophic lateral sclerosis.